428 related articles for article (PubMed ID: 33750914)
1. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer.
Cai L; Liu H; Huang F; Fujimoto J; Girard L; Chen J; Li Y; Zhang YA; Deb D; Stastny V; Pozo K; Kuo CS; Jia G; Yang C; Zou W; Alomar A; Huffman K; Papari-Zareei M; Yang L; Drapkin B; Akbay EA; Shames DS; Wistuba II; Wang T; Johnson JE; Xiao G; DeBerardinis RJ; Minna JD; Xie Y; Gazdar AF
Commun Biol; 2021 Mar; 4(1):314. PubMed ID: 33750914
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution.
Dora D; Rivard C; Yu H; Bunn P; Suda K; Ren S; Lueke Pickard S; Laszlo V; Harko T; Megyesfalvi Z; Moldvay J; Hirsch FR; Dome B; Lohinai Z
Mol Oncol; 2020 Sep; 14(9):1947-1965. PubMed ID: 32506804
[TBL] [Abstract][Full Text] [Related]
3. Loss of YAP1 defines neuroendocrine differentiation of lung tumors.
Ito T; Matsubara D; Tanaka I; Makiya K; Tanei ZI; Kumagai Y; Shiu SJ; Nakaoka HJ; Ishikawa S; Isagawa T; Morikawa T; Shinozaki-Ushiku A; Goto Y; Nakano T; Tsuchiya T; Tsubochi H; Komura D; Aburatani H; Dobashi Y; Nakajima J; Endo S; Fukayama M; Sekido Y; Niki T; Murakami Y
Cancer Sci; 2016 Oct; 107(10):1527-1538. PubMed ID: 27418196
[TBL] [Abstract][Full Text] [Related]
4. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.
Walter RF; Mairinger FD; Werner R; Vollbrecht C; Hager T; Schmid KW; Wohlschlaeger J; Christoph DC
Oncotarget; 2016 Apr; 7(15):20166-79. PubMed ID: 27064343
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
6. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells.
Kalari S; Jung M; Kernstine KH; Takahashi T; Pfeifer GP
Oncogene; 2013 Jul; 32(30):3559-68. PubMed ID: 22907430
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC
Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061
[No Abstract] [Full Text] [Related]
8. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
Horie M; Saito A; Ohshima M; Suzuki HI; Nagase T
Cancer Sci; 2016 Dec; 107(12):1755-1766. PubMed ID: 27627196
[TBL] [Abstract][Full Text] [Related]
9. Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype.
Vos MD; Scott FM; Iwai N; Treston AM
J Cell Biochem Suppl; 1996; 24():257-68. PubMed ID: 8806108
[TBL] [Abstract][Full Text] [Related]
10. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
11. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer.
Yu J; Wang S; Zhao W; Duan J; Wang Z; Chen H; Tian Y; Wang D; Zhao J; An T; Bai H; Wu M; Wang J
Clin Cancer Res; 2018 May; 24(9):2148-2158. PubMed ID: 29437792
[No Abstract] [Full Text] [Related]
13. Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells.
Wang XD; Hu R; Ding Q; Savage TK; Huffman KE; Williams N; Cobb MH; Minna JD; Johnson JE; Yu Y
Nat Commun; 2019 Jul; 10(1):3201. PubMed ID: 31324758
[TBL] [Abstract][Full Text] [Related]
14. Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.
Wang Q; Zeng F; Sun Y; Qiu Q; Zhang J; Huang W; Huang J; Huang X; Guo L
Clin Cancer Res; 2018 Feb; 24(4):950-962. PubMed ID: 29208667
[No Abstract] [Full Text] [Related]
15. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
16. Dynamic phenotypic reprogramming and chemoresistance induced by lung fibroblasts in small cell lung cancer.
Lu Y; Li H; Zhao P; Tian L; Liu Y; Sun X; Cheng Y
Sci Rep; 2024 Feb; 14(1):2884. PubMed ID: 38311608
[TBL] [Abstract][Full Text] [Related]
17. TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495.
Ye M; Wei T; Wang Q; Sun Y; Tang R; Guo L; Zhu W
Biochem Biophys Res Commun; 2017 Apr; 486(2):349-356. PubMed ID: 28302484
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
[TBL] [Abstract][Full Text] [Related]
19. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
20. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]